1 |
Rhea EM, Logsdon AF, Banks WA, Erickson ME. Intranasal Delivery: Effects on the Neuroimmune Axes and Treatment of Neuroinflammation. Pharmaceutics 2020;12:E1120. [PMID: 33233734 DOI: 10.3390/pharmaceutics12111120] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
|
2 |
Silva S, Bicker J, Fonseca C, Ferreira NR, Vitorino C, Alves G, Falcão A, Fortuna A. Encapsulated Escitalopram and Paroxetine Intranasal Co-Administration: In Vitro/In Vivo Evaluation. Front Pharmacol 2021;12:751321. [PMID: 34925013 DOI: 10.3389/fphar.2021.751321] [Reference Citation Analysis]
|
3 |
Cunha S, Swedrowska M, Bellahnid Y, Xu Z, Sousa Lobo J, Forbes B, Silva A. Thermosensitive in situ hydrogels of rivastigmine-loaded lipid-based nanosystems for nose-to-brain delivery: characterisation, biocompatibility, and drug deposition studies. International Journal of Pharmaceutics 2022. [DOI: 10.1016/j.ijpharm.2022.121720] [Reference Citation Analysis]
|
4 |
Gonçalves J, Silva S, Gouveia F, Bicker J, Falcão A, Alves G, Fortuna A. A combo-strategy to improve brain delivery of antiepileptic drugs: Focus on BCRP and intranasal administration. Int J Pharm 2021;593:120161. [PMID: 33307160 DOI: 10.1016/j.ijpharm.2020.120161] [Reference Citation Analysis]
|
5 |
Kumar R, Aadil KR, Mondal K, Mishra YK, Oupicky D, Ramakrishna S, Kaushik A. Neurodegenerative disorders management: state-of-art and prospects of nano-biotechnology. Crit Rev Biotechnol 2021;:1-33. [PMID: 34823433 DOI: 10.1080/07388551.2021.1993126] [Reference Citation Analysis]
|
6 |
Yaqub N, Wayne G, Birchall M, Song W. Recent advances in human respiratory epithelium models for drug discovery. Biotechnol Adv 2021;:107832. [PMID: 34481894 DOI: 10.1016/j.biotechadv.2021.107832] [Reference Citation Analysis]
|